Endocrine Society Annual Meeting

An ENDO 2023 analysis of data suggests women with PCOS were at a 47% greater risk of mortality relative to their counterparts without the common endocrine disorder.

A matched case-control study of nearly 100 women details the reduced effect of anti-obesity medications in those with a history of breast cancer and aromatase inhibitor use.

A phase 4 trial of men with hypogonadism in the US offers an overview of the potential risk of major cardiovascular events associated with use of testosterone replacement therapy.

The investigative team observed a U-shaped relationship between sleep duration and incident diabetes, with the greatest risk when sleep duration was ≥10 hours per day.

An analysis of US adults suggests MAFLD affects the Hispanic population at a higher prevalence relative to Black adults and White adults.

An analysis of data from the CLEAR Outcomes trial presented at ENDO 2023 suggests use of the non-statin lipid-lowering agent provided cardiovascular risk reduction comparable to statin therapy for each 1.0 mmol/L reduction in LDL-C.

A single-injection co-formulation of pramlitide and insulin may be a better alternative to separate administrations of both key treatments in adults with T1D, particularly following meals.

Stimulating steroid receptor co-activators may play a role in repairing heart tissue following severe myocardial infarction.

In ENDO 2021 data, approximately one-third of an observed COVID-19 patient population in Italy was still experiencing signs of thyroid inflammation after 3 months,

Many patients with genetic obesity disorder experience resistance to treatment, including intensive lifestyle therapy.

Evening and late-night preferences of women with GDM is linked to a significantly greater risk of preeclampsia and NICU treatment.

A post-hoc analysis of the AWARD-11 trial indicates that 4.5 mg of dulaglutide was effective in lowering and maintaining A1C levels <7% regardless of baseline levels.

An assessment of the world's largest twin registry found telling patterns of common autoimmune diseases including type 1 diabetes.

No significant differences in cardiovascular outcomes among patients receiving different GLP-1 agonists including exenatide extended-release, exenatide immediate-release, liraglutide, albiglutide, and dulaglutide.

Over the course of 16 weeks, OSA patients receiving CPAP treatment lost 5.7 pounds more on average than patients not receving CPAP therapy.

A year-long outpatient care study showed that patients with type 2 diabetes and comorbid cardiovascular disease are 5 times as likely to visit a cardiologist.

A new Puerto Rico-based trial shows that patients on add-on SGLT-2 inhibitors reported greater HbA1C reductions.

Decreases in anabolic hormone levels, vitamin D linked to weakening with age.

Could insulin could be dosed off of values from a continuous glucose monitor? Anne Peters, MD, and team sought to find out.

A project from the University of New Mexico looks to turn physicians to experts.

Bradley Miller, MD, University of Minnesota Academic Health Center hopes the team learns “good information” about how kids are growing on this dose of somavaratan that will then be confirmed in the phase 3 head-to-head with growth hormone daily.

Changes in adolescent brain structure are potentially associated with the onset of mental health disorders.

Study observed more time in target range, even when adjusted for increased activity.

Estetrol may provide the same testosterone suppression with less adverse effects.

“Today, hernia is really an endocrine disease,” according to Hong Zhao.

Although there are several unanswered questions in the field of menopause, but Cynthia Stuenkel, MD, University of California San Diego explained that many experts are beginning to understand the idea of hot flashes and how early and late they can occur in women.

The DIaMonD and GOLD Studies, which used continued glucose monitoring (CGM) in patients with type 1 diabetes who were in less than optimal control showed that the addition of CGM to these patients’ self-monitoring of blood glucose contributed to lower A1C, more time spent in range, less hypoglycemia, less severe hyperglycemia, and better quality of life.

"It is safe, it is easy, and it saves lives," prominent hormone therapy doctor said.

Does early-life environmental exposure to BPA (Bisphenol A) affect gene expression linked to fatty liver? That's the question Lindsey S. Trevino, PhD, Baylor College of Medicine and team sought to answer in their study using rat models.

Lindsey Triveño posits that early exposure can create NAFLD predisposition.